Loading clinical trials...

A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis

NCT07186114•Cairo University

View on ClinicalTrials.gov

Summary

This study aimed to assess the efficacy of MEBO® in the treatment of already established oral mucositis. This is a randomized controlled clinical trial. The study included 36 patients with established oral mucositis, divided into two groups. Patients were randomly allocated to either receive topically applied MEBO® ointment or Benzydamine Hydrochloride (Tantum Verde) mouthwash three times a day for two weeks. We assessed the World Health Organization mucositis score (WHO), the Oral Mucositis Assessment Scale (OMAS), and the Patient-Reported Oral Mucositis Symptom (PROMS) score at baseline, and after one and two weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who later on during radiotherapy developed oral mucositis with a severity of WHO score II or more and were over 18 years were then included in the study and allocated to one of the treatment groups .

Exclusion Criteria

•We excluded patients who were receiving any prophylactic agents and/or corticosteroids and those who would not sign the informed consent.

Locations (2)

Faculty of Dentistry - Cairo University

Cairo, Egypt

Cairo University

Cairo, Egypt

Key Dates

Start Date

March 1, 2023

Primary Completion Date

December 14, 2024

Completion Date

December 14, 2024

Last Updated

September 22, 2025

Enrollment

ACTUAL participants

Conditions

Oral Mucositis (Ulcerative) Due to Radiation

Interventions

MEBO Wound Ointment (MEBO)

DRUG

Tantum Verde® mouthwash

DRUG

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

NCT03972527

Oral Mucositis (Ulcerative)Oral Mucositis (Ulcerative) Due to Radiation+2 more

View study

COMPLETEDPHASE2

Melatonin for Prevention of Radiation Induced Oral Mucositis

NCT03833570

Oral Mucositis (Ulcerative) Due to Radiation

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis

Inclusion Criteria

Exclusion Criteria

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Melatonin for Prevention of Radiation Induced Oral Mucositis

Dexpanthenol Mouthwash to Treat Oral Mucositis